Effect of an alpha-glucosidase inhibitor on intestinal fermentation and faecal lipids in diabetic patients.
Eight non-insulin-dependent diabetes mellitus patients, in whom oral hypoglycaemic agents were not effective, were treated with an alpha-glucosidase inhibitor, AO-128 (0.9 mg/day) for 6 months. After 6 months of treatment there was a statistically significant decrease in the blood glucose level 1 and 2 h postprandially. The 2 h blood glucose level was also significantly reduced after 2 months' treatment. The insulin and HbA1c levels after 2 and 6 months' treatment were lower than those before administration. Faecal weight, the frequency of bowel movements, the ratio of hydroxy fatty acids to total fatty acids, and faecal short-chain carboxylic acid content were all increased significantly during treatment. The initially hard stools became normal or soft, although no actual diarrhoea developed. Both faecal bile-acid excretion and the ratio of primary bile acids to total bile acids were increased significantly after 2 months, but they showed some recovery towards the pretreatment levels after 6 months' treatment. There was no distinct change in neutral sterol and fatty acid excretion. Breath hydrogen excretion showed a slight increase after treatment. These results suggest that intestinal fermentation was promoted and the intestinal transit time was shortened by AO-128 administration.
Nakamura
T
T
Third Department of Internal Medicine, Hirosaki University School of Medicine, Japan.
Takebe
K
K
Kudoh
K
K
Terada
A
A
Tandoh
Y
Y
Arai
Y
Y
Yamada
N
N
Ishii
M
M
Kikuchi
H
H
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003511:Cyclohexanols / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D003927:Diet, Diabetic; D004435:Eating; D002149:Energy Intake; D005243:Feces / Q000737:chemistry*; D005260:Female; D005285:Fermentation; D005905:Glyburide / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D017211:Treatment Failure
D001786:Blood Glucose; D003511:Cyclohexanols; D005905:Glyburide; D006442:Glycated Hemoglobin; D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin; C054577:AO 128